Plasticity of T cell differentiation and cytokine signature: A double-edged sword for immune responses

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 90-105

  Salem, Mohamed Labib ^a,b,i   Alenzi, Faris Q ^c   Nath, Narender ^a   El Naggar, Sabry A ^b   Al Khami, Amir A ^b   Al Jabri, Ali A ^d   Arif, Jamal ^e   El Nashar, Imam M ^f   El Tounsi, Iman ^g   Wyse, Richard K H ^h  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Tanta University   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d SULTAN QABOOS UNIVERSITY   (Oman)

^e INTEGRAL UNIVERSITY   (India)

^f KING KHALID UNIVERSITY   (Saudi Arabia)

^g MENOUFIA UNIVERSITY   (Egypt)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adoptive cell therapy; Autoimmunity; Cancer; Cytokines; Immunity; Inflammation; Regulatory cells; Suppressor T cells; Th1; Th17.; Th2

Indexed keywords

ALPHA INTERFERON; APC PROTEIN; B7 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GRAFT REJECTION; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INFLAMMATION; INFLAMMATORY DISEASE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOTOXICITY; MONOTHERAPY; PLASTICITY; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD; VIRUS REPLICATION;

EID: 70350033476     PISSN: 18715222     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152209789000687     Document Type: Article

References (203)

1. Villinger, F. Cytokines as clinical adjuvants: how far are we? Expert Rev. Vaccines, 2003, 2(2), 317-326.
2. Elenkov, I.J.; Iezzoni, D.G.; Daly, A.; Harris, A.G.; Chrousos, G.P. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation, 2005, 12(5), 255-269.
3. Mosmann, T.R. Cytokines, differentiation and functions of subsets of CD4 and CD8 T cells. Behring Inst. Mitt., 1995, (96), 1-6.
4. Ahmadzadeh, M.; Farber, D.L. Functional plasticity of an antigen-specific memory CD4 T cell population. Proc. Natl. Acad. Sci. USA, 2002, 99(18), 11802-11807.
5. Weaver, C.T.; Murphy, K.M. T-cell subsets: the more the merrier. Curr Biol., 2007, 17(2), R61-R63.
6. Chaouat, G.; Ledee-Bataille, N.; Dubanchet, S.; Zourbas, S.; Sandra, O.; Martal, J. TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm. Int. Arch. Allergy Immunol., 2004, 134(2), 93-119.
7. Behrens, G.; Li, M.; Smith, C.M.; Belz, G.T.; Mintern, J.; Carbone, F.R.; Heath, W.R. Helper T cells, dendritic cells and CTL Immunity. Immunol. Cell Biol., 2004, 82(1), 84-90.
8. Kennedy, R.; Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev., 2008, 222, 129-144.
9. Woodland, D.L.; Dutton, R.W. Heterogeneity of CD4(+) and CD8(+) T cells. Curr. Opin. Immunol., 2003, 15(3), 336-342.
10. Wurster, A.L.; Rodgers, V.L.; Satoskar, A.R.; Whitters, M.J.; Young, D.A.; Collins, M.; Grusby, M.J. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J. Exp. Med., 2002, 196(7), 969-977.
11. Smeltz, R.B.; Chen, J.; Ehrhardt, R.; Shevach, E.M. Role of IFN-gamma in Th1 differentiation: IFN-gamma regulates IL-18R alpha expression by preventing the negative effects of IL-4 and by inducing/maintaining IL-12 receptor beta 2 expression. J. Immunol., 2002, 168(12), 6165-6172.
12. Zhang, Y.; Apilado, R.; Coleman, J.; Ben-Sasson, S.; Tsang, S.; Hu-Li, J.; Paul, W.E.; Huang, H. Interferon gamma stabilizes the T helper cell type 1 phenotype. J. Exp. Med., 2001, 194(2), 165-172.
13. Wang, X.; Mosmann, T. In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4-or IFN-gamma-secreting cells. J. Exp. Med., 2001, 194(8), 1069-1080.
14. Chang, J.H.; McCluskey, P.J.; Wakefield, D. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br. J. Ophthalmol., 2006, 90(1), 103-108.
15. Weaver, C.T.; Murphy, K.M. The central role of the Th17 lineage in regulating the inflammatory/autoimmune axis. Semin. Immunol., 2007, 19(6), 351-352.
16. Awasthi, A.; Kuchroo, V.K. Th17 cells: from precursors to players in inflammation and infection. Int. Immunol., 2009, 21(5), 489-498.
17. Aranami, T.; Yamamura, T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int., 2008, 57(2), 115-120.
18. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 1995, 155(3), 1151-1164.
19. Taams, L.S.; Akbar, A.N. Peripheral generation and function of CD4+CD25+ regulatory T cells. Curr. Top. Microbiol. Immunol., 2005, 293, 115-131.
20. Mills, K.H.; McGuirk, P. Antigen-specific regulatory T cells - their induction and role in infection. Semin. Immunol., 2004, 16(2), 107-117.
21. Murakami, M.; Sakamoto, A.; Bender, J.; Kappler, J.; Marrack, P. CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc. Natl. Acad. Sci. USA, 2002, 99(13), 8832-8837.
22. Mills, K.H. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol., 2004, 4(11), 841-855.
23. Curiel, T.J. Regulatory T cells and treatment of cancer. Curr. Opin. Immunol., 2008, 20(2), 241-246.
24. Mahnke, K.; Schonfeld, K.; Fondel, S.; Ring, S.; Karakhanova, S.; Wiedemeyer, K.; Bedke, T.; Johnson, T.S.; Storn, V.; Schallenberg, S.; Enk, A.H. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer, 2007, 120(12), 2723-2733.
25. Dannull, J.; Su, Z.; Rizzieri, D.; Yang, B.K.; Coleman, D.; Yancey, D.; Zhang, A.; Dahm, P.; Chao, N.; Gilboa, E.; Vieweg, J. Enhancement of vaccine-mediated antitumor-immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest., 2005, 115(12), 3623-3633.
26. Schabowsky, R.H.; Madireddi, S.; Sharma, R.; Yolcu, E.S.; Shirwan, H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs, 2007, 8(12), 1002-1008.
27. Audia, S.; Nicolas, A.; Cathelin, D.; Larmonier, N.; Ferrand, C.; Foucher, P.; Fanton, A.; Bergoin, E.; Maynadie, M.; Arnould, L.; Bateman, A.; Lorcerie, B.; Solary, E.; Chauffert, B.; Bonnotte, B. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin. Exp. Immunol., 2007, 150(3), 523-530.
28. Kitani, A.; Xu, L. Regulatory T cells and the induction of IL-17. Mucosal. Immunol., 2008, 1(Suppl. 1), S43-S46.
29. Pomie, C.; Menager-Marcq, I.; van Meerwijk, J.P. Murine CD8+ regulatory T lymphocytes: the new era. Hum. Immunol., 2008, 69(11), 708-714.
30. Scotto, L.; Naiyer, A.J.; Galluzzo, S.; Rossi, P.; Manavalan, J.S.; Kim-Schulze, S.; Fang, J.; Favera, R.D.; Cortesini, R.; Suciu-Foca, N. Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28-T suppressor cells. Hum. Immunol., 2004, 65(11), 1297-1306.
31. Liu, J.; Liu, Z.; Witkowski, P.; Vlad, G.; Manavalan, J.S.; Scotto, L.; Kim-Schulze, S.; Cortesini, R.; Hardy, M.A.; Suciu-Foca, N. Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl. Immunol., 2004, 13(4), 239-247.
32. Manavalan, J.S.; Kim-Schulze, S.; Scotto, L.; Naiyer, A.J.; Vlad, G.; Colombo, P.C.; Marboe, C.; Mancini, D.; Cortesini, R.; Suciu-Foca, N. Alloantigen specific CD8+ CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int. Immunol., 2004, 16(8), 1055-1068.
33. Waldmann, H.; Graca, L.; Cobbold, S.; Adams, E.; Tone, M.; Tone, Y. Regulatory T cells and organ transplantation. Semin. Immunol., 2004, 16(2), 119-126.
34. Ciubotariu, R.; Colovai, A.I.; Pennesi, G.; Liu, Z.; Smith, D.; Berlocco, P.; Cortesini, R.; Suciu-Foca, N. Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J. Immunol., 1998, 161(10), 5193-5202.
35. Colovai, A.I.; Liu, Z.; Ciubotariu, R.; Lederman, S.; Cortesini, R.; Suciu-Foca, N. Induction of xenoreactive CD4+ T-cell anergy by suppressor CD8+CD28- T cells. Transplantation, 2000, 69(7), 1304-1310.
36. Filaci, G.; Fenoglio, D.; Fravega, M.; Ansaldo, G.; Borgonovo, G.; Traverso, P.; Villaggio, B.; Ferrera, A.; Kunkl, A.; Rizzi, M.; Ferrera, F.; Balestra, P.; Ghio, M.; Contini, P.; Setti, M.; Olive, D.; Azzarone, B.; Carmignani, G.; Ravetti, J.L.; Torre, G.; Indiveri, F. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J. Immunol., 2007, 179(7), 4323-4334.
37. Najafian, N.; Chitnis, T.; Salama, A.D.; Zhu, B.; Benou, C.; Yuan, X.; Clarkson, M.R.; Sayegh, M.H.; Khoury, S.J. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J. Clin. Invest., 2003, 112(7), 1037-1048.
38. Akl, A.; Luo, S.; Wood, K.J. Induction of transplantation tolerance-the potential of regulatory T cells. Transpl. Immunol., 2005, 14(3-4), 225-230.
39. Li, J.; Liu, Z.; Jiang, S.; Cortesini, R.; Lederman, S.; Suciu-Foca, N. T suppressor lymphocytes inhibit NF-kappa B-mediated transcription of CD86 gene in APC. J. Immunol., 1999, 163(12), 6386-6392.
40. Chang, C.C.; Ciubotariu, R.; Manavalan, J.S.; Yuan, J.; Colovai, A.I.; Piazza, F.; Lederman, S.; Colonna, M.; Cortesini, R.; Dalla-Favera, R.; Suciu-Foca, N. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol., 2002, 3(3), 237-243.
41. Manavalan, J.S.; Rossi, P.C.; Vlad, G.; Piazza, F.; Yarilina, A.; Cortesini, R.; Mancini, D.; Suciu-Foca, N. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl. Immunol., 2003, 11(3-4), 245-258.
42. Liu, Y.; Chen, N.; Chen, G.; You, P. The protective effect of CD8+CD28- T suppressor cells on the acute rejection responses in rat liver transplantation. Transplant. Proc., 2007, 39(10), 3396-3403.
43. Sindhi, R.; Manavalan, J.S.; Magill, A.; Suciu-Foca, N.; Zeevi, A. Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28- T-suppressor cells. Hum. Immunol., 2005, 66(3), 252-257.
44. Mueller, T.F. Phenotypic changes with immunosuppression in human recipients. Front. Biosci., 2003, 8, d1254-1274.
45. Zozulya, A.L.; Wiendl, H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Hum. Immunol., 2008, 69(11), 797-804.
46. Suzuki, M.; Konya, C.; Goronzy, J.J.; Weyand, C.M. Inhibitory CD8+ T cells in autoimmune disease. Hum. Immunol., 2008, 69(11), 781-789.
47. Davila, E.; Kang, Y.M.; Park, Y.W.; Sawai, H.; He, X.; Pryshchep, S.; Goronzy, J.J.; Weyand, C.M. Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis. J. Immunol., 2005, 174(11), 7292-7301.
48. Argiles, J.M.; Lopez-Soriano, F.J. The role of cytokines in cancer cachexia. Med. Res. Rev., 1999, 19(3), 223-248.
49. Salem, M.L. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr. Drug Targets Inflamm. Allergy, 2004, 3(1), 97-104.
50. Piccinni, M.P.; Scaletti, C.; Maggi, E.; Romagnani, S. Role of hormone-controlled Th1- and Th2-type cytokines in successful pregnancy. J. Neuroimmunol., 2000, 109(1), 30-33.
51. Piccinni, M.P. T cells in normal pregnancy and recurrent pregnancy loss. Reprod. Biomed. Online, 2006, 13(6), 840-844.
52. Andreakos, E.T.; Foxwell, B.M.; Brennan, F.M.; Maini, R.N.; Feldmann, M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev., 2002, 13(4-5), 299-313.
53. O'Shea, J.J.; Ma, A.; Lipsky, P. Cytokines and autoimmunity. Nat. Rev. Immunol., 2002, 2(1), 37-45.
54. Ichinose, M.; Barnes, P.J. Cytokine-directed therapy in asthma. Curr. Drug Targets Inflamm. Allergy, 2004, 3(3), 263-269.
55. Arai, K.I.; Lee, F.; Miyajima, A.; Miyatake, S.; Arai, N.; Yokota, T. Cytokines: coordinators of immune and inflammatory responses. Annu. Rev. Biochem., 1990, 59, 783-836.
56. Wadia, P.P.; Tambur, A.R. Yin and yang of cytokine regulation in solid organ graft rejection and tolerance. Clin. Lab. Med., 2008, 28(3), 469-479, vii-viii.
57. Brewer, J.M.; Alexander, J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell Mol. Ther., 1997, 3(4), 233-246.
58. Rizza, P.; Ferrantini, M.; Capone, I.; Belardelli, F. Cytokines as natural adjuvants for vaccines: where are we now? Trends Immunol., 2002, 23(8), 381-383.
59. Estaquier, J.; Idziorek, T.; Zou, W.; Emilie, D.; Farber, C.M.; Bourez, J.M.; Ameisen, J.C. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J. Exp. Med., 1995, 182(6), 1759-1767.
60. Chamoto, K.; Kosaka, A.; Tsuji, T.; Matsuzaki, J.; Sato, T.; Takeshima, T.; Iwakabe, K.; Togashi, Y.; Koda, T.; Nishimura, T. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci., 2003, 94(10), 924-928.
61. Lai, Y.G.; Gelfanov, V.; Gelfanova, V.; Kulik, L.; Chu, C.L.; Jeng, S.W.; Liao, N.S. IL-15 promotes survival but not effector function differentiation of CD8+ TCRalphabeta+ intestinal intraepithelial lymphocytes. J. Immunol., 1999, 163(11), 5843-5850.
62. Tsuda, K.; Toda, M.; Kim, G.; Saitoh, K.; Yoshimura, S.; Yoshida, T.; Taki, W.; Waga, S.; Kuribayashi, K. Survivalpromoting activity of IL-7 on IL-2-dependent cytotoxic T lymphocyte clones: resultant induction of G1 arrest. J. Immunol. Methods, 2000, 236, (1-2), 37-51.
63. Schluns, K.S.; Kieper, W.C.; Jameson, S.C.; Lefrancois, L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol., 2000, 1(5), 426-432.
64. Fry, T.J.; Mackall, C.L. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol., 2001, 22(10), 564-571.
65. Berard, M.; Brandt, K.; Bulfone Paus, S.; Tough, D.F. IL15 promotes the survival of naive and memory phenotype CD8+ T cells. J. Immunol., 2003, 170(10), 5018-5026.
66. Bulfone-Paus, S.; Ungureanu, D.; Pohl, T.; Lindner, G.; Paus, R.; Ruckert, R.; Krause, H.; Kunzendorf, U., Interleukin- 15 protects from lethal apoptosis in vivo. Nat. Med., 1997, 3(10), 1124-1128.
67. Vella, A.T.; Dow, S.; Potter, T.A.; Kappler, J.; Marrack, P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 1998, 95(7), 3810-3815.
68. Belardelli, F.; Ferrantini, M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol., 2002, 23(4), 201-208.
69. Nguyen, C.L.; Salem, M.L.; Rubinstein, M.P.; Demcheva, M.; Vournakis, J.N.; Cole, D.J.; Gillanders, W.E. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine, 2003, 21(19-20), 2318-2328.
70. Rubinstein, M.P.; Kadima, A.N.; Salem, M.L.; Nguyen, C.L.; Gillanders, W.E.; Cole, D.J. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J. Immunol., 2002, 169(9), 4928-4935.
71. Terando, A.; Roessler, B.; Mule, J.J. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther., 2004, 11(3), 165-173.
72. Riedl, K.; Baratelli, F.; Batra, R.K.; Yang, S.C.; Luo, J.; Escuadro, B.; Figlin, R.; Strieter, R.; Sharma, S.; Dubinett, S. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol. Cancer, 2003, 2, 35.
73. Tolba, K.A.; Bowers, W.J.; Muller, J.; Housekneckt, V.; Giuliano, R.E.; Federoff, H.J.; Rosenblatt, J.D. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res., 2002, 62(22), 6545-6551.
74. Wiley, H.E.; Gonzalez, E.B.; Maki, W.; Wu, M.T.; Hwang, S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst., 2001, 93(21), 1638-1643.
75. Vicari, A.P.; Ait-Yahia, S.; Chemin, K.; Mueller, A.; Zlotnik, A.; Caux, C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol., 2000, 165(4), 1992-2000.
76. Yang, S.C.; Hillinger, S.; Riedl, K.; Zhang, L.; Zhu, L.; Huang, M.; Atianzar, K.; Kuo, B.Y.; Gardner, B.; Batra, R.K.; Strieter, R.M.; Dubinett, S.M.; Sharma, S. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res., 2004, 10(8), 2891-2901.
77. Baratelli, F.; Takedatsu, H.; Hazra, S.; Peebles, K.; Luo, J.; Kurimoto, P.S.; Zeng, G.; Batra, R.K.; Sharma, S.; Dubinett, S.M.; Lee, J.M. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J. Transl. Med., 2008, 6, 38.
78. Yang, S.C.; Batra, R.K.; Hillinger, S.; Reckamp, K.L.; Strieter, R.M.; Dubinett, S.M.; Sharma, S. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res., 2006, 66(6), 3205-3213.
79. Okada, N.; Mori, N.; Koretomo, R.; Okada, Y.; Nakayama, T.; Yoshie, O.; Mizuguchi, H.; Hayakawa, T.; Nakagawa, S.; Mayumi, T.; Fujita, T.; Yamamoto, A. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther., 2005, 12(2), 129-139.
80. Rosenberg, S.A.; Restifo, N.P.; Yang, J.C.; Morgan, R.A.; Dudley, M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer, 2008, 8(4), 299-308.
81. Dudley, M.E.; Rosenberg, S.A. Adoptive cell transfer therapy. Semin. Oncol., 2007, 34(6), 524-531.
82. Salem, M.L.; Kadima, A.N.; El-Naggar, S.A.; Rubinstein, M.P.; Chen, Y.; Gillanders, W.E.; Cole, D.J. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother., 2007, 30(1), 40-53.
83. Hadden, J.; Verastegui, E.; Barrera, J.L.; Kurman, M.; Meneses, A.; Zinser, J.W.; de la Garza, J.; Hadden, E. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int. Immunopharmacol., 2003, 3(8), 1073-1081.
84. Cole, D.J.; Sanda, M.G.; Yang, J.C.; Schwartzentruber, D.J.; Weber, J.; Ettinghausen, S.E.; Pockaj, B.A.; Kim, H.I.; Levin, R.D.; Pogrebniak, H.W.; Balkissoon, J.; Fenton, R.M.; DeBarge, L.R.; Kaye, J.; Rosenberg, S.A.; Parkinson, D.R. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J. Natl. Cancer Inst., 1994, 86(1), 39-45.
85. Leveque, L.; Deknuydt, F.; Bioley, G.; Old, L.J.; Matsuzaki, J.; Odunsi, K.; Ayyoub, M.; Valmori, D. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. J. Immunother., 2009, 32(2), 101-108.
86. Balkwill, F.R.; Griffin, D.B.; Lee, A.E. Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivo. Eur. J. Cancer Clin. Oncol., 1989, 25(10), 1481-1486.
87. Belardelli, F.; Ferrantini, M.; Proietti, E.; Kirkwood, J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev., 2002, 13(2), 119-134.
88. Brassard, D.L.; Grace, M.J.; Bordens, R.W. Interferon-alpha as an immunotherapeutic protein. J. Leukoc. Biol., 2002, 71(4), 565-581.
89. Legha, S.S. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin. Oncol., 1997, 24(1 Suppl. 4), S39-S43.
90. Mitchell, M.S. Combinations of anticancer drugs and immunotherapy. Cancer Immunol. Immunother., 2003, 52(11), 686-692.
91. Mitchell, M.S. Immunotherapy as part of combinations for the treatment of cancer. Int. Immunopharmacol., 2003, 3(8), 1051-1059.
92. Yi, T.; Pathak, M.K.; Lindner, D.J.; Ketterer, M.E.; Farver, C.; Borden, E.C. Anticancer activity of sodium stibogluconate in synergy with IFNs. J. Immunol., 2002, 169(10), 5978-5985.
93. Peretz, Y.; Zhou, Z.F.; Halwani, F.; Prud'homme, G.J. In vivo generation of dendritic cells by intramuscular codelivery of FLT3 ligand and GM-CSF plasmids. Mol. Ther., 2002, 6(3), 407-414.
94. Rosenberg, S.A.; Yang, J.C.; Robbins, P.F.; Wunderlich, J.R.; Hwu, P.; Sherry, R.M.; Schwartzentruber, D.J.; Topalian, S.L.; Restifo, N.P.; Filie, A.; Chang, R.; Dudley, M.E. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother., 2003, 26(5), 385-393.
95. Dobrzanski, M.J.; Reome, J.B.; Hollenbaugh, J.A.; Dutton, R.W. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J. Immunol., 2004, 172(3), 1380-1390.
96. Dobrzanski, M.J.; Reome, J.B.; Hollenbaugh, J.A.; Hylind, J.C.; Dutton, R.W. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res., 2004, 64(1), 406-414.
97. Hollenbaugh, J.A.; Reome, J.; Dobrzanski, M.; Dutton, R.W. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J. Immunol., 2004, 173(3), 1738-1743.
98. Reome, J.B.; Hylind, J.C.; Dutton, R.W.; Dobrzanski, M.J. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin. Immunol., 2004, 111(1), 69-81.
99. Klebanoff, C.A.; Gattinoni, L.; Torabi-Parizi, P.; Kerstann, K.; Cardones, A.R.; Finkelstein, S.E.; Palmer, D.C.; Antony, P.A.; Hwang, S.T.; Rosenberg, S.A.; Waldmann, T.A.; Restifo, N.P. Central memory self/ tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA, 2005, 102(27), 9571-9576.
100. Schluns, K.S.; Lefrancois, L. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol., 2003, 3(4), 269-279.
101. Klebanoff, C.A.; Finkelstein, S.E.; Surman, D.R.; Lichtman, M.K.; Gattinoni, L.; Theoret, M.R.; Grewal, N.; Spiess, P.J.; Antony, P.A.; Palmer, D.C.; Tagaya, Y.; Rosenberg, S.A.; Waldmann, T.A.; Restifo, N.P. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA, 2004, 101(7), 1969-1974.
102. Diaz-Montero, C.M.; El Naggar, S.; Al Khami, A.; El Naggar, R.; Montero, A.J.; Cole, D.J.; Salem, M.L. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol. Immunother., 2008, 57(4), 563-572.
103. Muranski, P.; Boni, A.; Wrzesinski, C.; Citrin, D.E.; Rosenberg, S.A.; Childs, R.; Restifo, N.P. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat. Clin. Pract. Oncol., 2006, 3(12), 668-681.
104. Finkelstein, S.E.; Heimann, D.M.; Klebanoff, C.A.; Antony, P.A.; Gattinoni, L.; Hinrichs, C.S.; Hwang, L.N.; Palmer, D.C.; Spiess, P.J.; Surman, D.R.; Wrzesiniski, C.; Yu, Z.; Rosenberg, S.A.; Restifo, N.P. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J. Leukoc. Biol., 2004, 76(2), 333-337.
105. Salem, M.L.; Diaz-Montero, C.M.; Al-Khami, A.A.; El-Naggar, S.A.; Naga, O.; Montero, A.J.; Khafagy, A.; Cole, D.J. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J. Immunol., 2009, 182(4), 2030-2040.
106. Agrawal, L.; Lu, X.; Jin, Q.; Alkhatib, G. Anti-HIV therapy: Current and future directions. Curr. Pharm. Des., 2006, 12(16), 2031-2055.
107. Ndhlovu, L.C.; Chapman, J.M.; Jha, A.R.; Snyder-Cappione, J.E.; Pagan, M.; Leal, F.E.; Boland, B.S.; Norris, P.J.; Rosenberg, M.G.; Nixon, D.F. Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS, 2008, 22(8), 990-992.
108. Alfano, M.; Crotti, A.; Vicenzi, E.; Poli, G. New players in cytokine control of HIV infection. Curr. HIV/AIDS Rep., 2008, 5(1), 27-32.
109. Maek, A.N.W.; Buranapraditkun, S.; Klaewsongkram, J.; Ruxrungtham, K. Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection. Viral Immunol., 2007, 20(1), 66-75.
110. Fowler, D.H.; Gress, R.E. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk. Lymphoma, 2000, 38(3-4), 221-234.
111. Salem, M.L.; Matsuzaki, G.; Kishihara, K.; Madkour, G.A.; Nomoto, K. beta-estradiol suppresses T cell-mediated delayed-type hypersensitivity through suppression of antigen-presenting cell function and Th1 induction. Int. Arch. Allergy Immunol., 2000, 121(2), 161-169.
112. Salem, M.L.; Matsuzaki, G.; Madkour, G.A.; Nomoto, K. Beta-estradiol-induced decrease in IL-12 and TNF-alpha expression suppresses macrophage functions in the course of Listeria monocytogenes infection in mice. Int. J. Immunopharmacol., 1999, 21(8), 481-497.
113. Nath, N.; Giri, S.; Prasad, R.; Salem, M.L.; Singh, A.K.; Singh, I. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol., 2005, 175(1), 566-574.
114. Salem, M.L.; Kishihara, K.; Abe, K.; Matsuzaki, G.; Nomoto, K. N-3 polyunsaturated fatty acids accentuate B16 melanoma growth and metastasis through suppression of tumoricidal function of T cells and macrophages. Anticancer Res., 2000, 20(5A), 3195-3203.
115. Salem, M.L. Systemic treatment with n-6 polyunsaturated fatty acids attenuates EL4 thymoma growth and metastasis through enhancing specific and non-specific anti-tumor cytolytic activities and production of TH1 cytokines. Int. Immunopharmacol., 2005, 5(6), 947-960.
116. Dinarello, C.A. Anti-cytokine therapeutics and infections. Vaccine, 2003, 21(Suppl. 2), S24-34.
117. Andreakos, E. Targeting cytokines in autoimmunity: new approaches, new promise. Expert Opin. Biol. Ther., 2003, 3(3), 435-447.
118. Kauffman, C.L.; Aria, N.; Toichi, E.; McCormick, T.S.; Cooper, K.D.; Gottlieb, A.B.; Everitt, D.E.; Frederick, B.; Zhu, Y.; Graham, M.A.; Pendley, C.E.; Mascelli, M.A. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol., 2004, 123(6), 1037-1044.
119. Ferber, I.A.; Brocke, S.; Taylor-Edwards, C.; Ridgway, W.; Dinisco, C.; Steinman, L.; Dalton, D.; Fathman, C.G. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol., 1996, 156(1), 5-7.
120. Chu, C.Q.; Wittmer, S.; Dalton, D.K. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med., 2000, 192(1), 123-128.
121. Dalton, D.K.; Haynes, L.; Chu, C.Q.; Swain, S.L.; Wittmer, S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J. Exp. Med., 2000, 192(1), 117-122.
122. Willenborg, D.O.; Fordham, S.A.; Staykova, M.A.; Ramshaw, I.A.; Cowden, W.B. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol., 1999, 163(10), 5278-5286.
123. Manoury-Schwartz, B.; Chiocchia, G.; Bessis, N.; Abehsira- Amar, O.; Batteux, F.; Muller, S.; Huang, S.; Boissier, M.C.; Fournier, C. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J. Immunol., 1997, 158(11), 5501-5506.
124. Vermeire, K.; Heremans, H.; Vandeputte, M.; Huang, S.; Billiau, A.; Matthys, P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol., 1997, 158(11), 5507-5513.
125. Ortmann, R.A.; Shevach, E.M. Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clin. Immunol., 2001, 98(1), 109-118.
126. Brem-Exner, B.G.; Sattler, C.; Hutchinson, J.A.; Koehl, G.E.; Kronenberg, K.; Farkas, S.; Inoue, S.; Blank, C.; Knechtle, S.J.; Schlitt, H.J.; Fandrich, F.; Geissler, E.K. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J. Immunol., 2008, 180(1), 335-349.
127. Markees, T.G.; Phillips, N.E.; Gordon, E.J.; Noelle, R.J.; Shultz, L.D.; Mordes, J.P.; Greiner, D.L.; Rossini, A.A. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J. Clin. Invest., 1998, 101(11), 2446-2455.
128. Bishop, D.K.; Chan Wood, S.; Eichwald, E.J.; Orosz, C.G. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions. J. Immunol., 2001, 166(5), 3248-3255.
129. Saleem, S.; Konieczny, B.T.; Lowry, R.P.; Baddoura, F.K.; Lakkis, F.G. Acute rejection of vascularized heart allografts in the absence of IFNgamma. Transplantation, 1996, 62(12), 1908-1911.
130. Konieczny, B.T.; Dai, Z.; Elwood, E.T.; Saleem, S.; Linsley, P.S.; Baddoura, F.K.; Larsen, C.P.; Pearson, T.C.; Lakkis, F.G. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J. Immunol., 1998, 160(5), 2059-2064.
131. Guillonneau, C.; Hill, M.; Hubert, F.X.; Chiffoleau, E.; Herve, C.; Li, X.L.; Heslan, M.; Usal, C.; Tesson, L.; Menoret, S.; Saoudi, A.; Le Mauff, B.; Josien, R.; Cuturi, M.C.; Anegon, I. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J. Clin. Invest., 2007, 117(4), 1096-1106.
132. Feng, G.; Gao, W.; Strom, T.B.; Oukka, M.; Francis, R.S.; Wood, K.J.; Bushell, A. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur. J. Immunol., 2008, 38(9), 2512-2527.
133. Murphy, W.J.; Welniak, L.; Back, T.; Hixon, J.; Subleski, J.; Seki, N.; Wigginton, J.M.; Wilson, S.E.; Blazar, B.R.; Malyguine, A.M.; Sayers, T.J.; Wiltrout, R.H. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J. Immunol., 2003, 170(5), 2727-2733.
134. Sigidin, Y.A.; Loukina, G.V.; Skurkovich, B.; Skurkovich, S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand. J. Rheumatol., 2001, 30(4), 203-207.
135. Afzali, B.; Lombardi, G.; Lechler, R.I.; Lord, G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol., 2007, 148(1), 32-46.
136. Kleinschek, M.A.; Boniface, K.; Sadekova, S.; Grein, J.; Murphy, E.E.; Turner, S.P.; Raskin, L.; Desai, B.; Faubion, W.A.; de Waal Malefyt, R.; Pierce, R.H.; McClanahan, T.; Kastelein, R.A. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med., 2009, 206(3), 525-534.
137. Annunziato, F.; Cosmi, L.; Santarlasci, V.; Maggi, L.; Liotta, F.; Mazzinghi, B.; Parente, E.; Fili, L.; Ferri, S.; Frosali, F.; Giudici, F.; Romagnani, P.; Parronchi, P.; Tonelli, F.; Maggi, E.; Romagnani, S. Phenotypic and functional features of human Th17 cells. J. Exp. Med., 2007, 204(8), 1849-1861.
138. Pene, J.; Chevalier, S.; Preisser, L.; Venereau, E.; Guilleux, M.H.; Ghannam, S.; Moles, J.P.; Danger, Y.; Ravon, E.; Lesaux, S.; Yssel, H.; Gascan, H. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J. Immunol., 2008, 180(11), 7423-7430.
139. Hsieh, H.G.; Loong, C.C.; Lin, C.Y. Interleukin-17 induces src/MAPK cascades activation in human renal epithelial cells. Cytokine, 2002, 19(4), 159-174.
140. Loong, C.C.; Hsieh, H.G.; Lui, W.Y.; Chen, A.; Lin, C.Y. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J. Pathol., 2002, 197(3), 322-332.
141. Van Kooten, C.; Boonstra, J.G.; Paape, M.E.; Fossiez, F.; Banchereau, J.; Lebecque, S.; Bruijn, J.A.; De Fijter, J.W.; Van Es, L.A.; Daha, M.R. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J. Am. Soc. Nephrol., 1998, 9(8), 1526-1534.
142. Yoshida, S.; Haque, A.; Mizobuchi, T.; Iwata, T.; Chiyo, M.; Webb, T.J.; Baldridge, L.A.; Heidler, K.M.; Cummings, O.W.; Fujisawa, T.; Blum, J.S.; Brand, D.D.; Wilkes, D.S. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am. J. Transplant., 2006, 6(4), 724-735.
143. Vanaudenaerde, B.M.; Dupont, L.J.; Wuyts, W.A.; Verbeken, E.K.; Meyts, I.; Bullens, D.M.; Dilissen, E.; Luyts, L.; Van Raemdonck, D.E.; Verleden, G.M. The role of interleukin-17 during acute rejection after lung transplantation. Eur. Respir. J., 2006, 27(4), 779-787.
144. Li, J.; Simeoni, E.; Fleury, S.; Dudler, J.; Fiorini, E.; Kappenberger, L.; von Segesser, L.K.; Vassalli, G. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur. J. Cardiothorac. Surg., 2006, 29(5), 779-783.
145. Tang, J.L.; Subbotin, V.M.; Antonysamy, M.A.; Troutt, A.B.; Rao, A.S.; Thomson, A.W. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation, 2001, 72(2), 348-350.
146. Yuan, X.; Paez-Cortez, J.; Schmitt-Knosalla, I.; D'Addio, F.; Mfarrej, B.; Donnarumma, M.; Habicht, A.; Clarkson, M.R.; Iacomini, J.; Glimcher, L.H.; Sayegh, M.H.; Ansari, M.J. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J. Exp. Med., 2008, 205(13), 3133-3144.
147. Carlson, M.J.; West, M.L.; Coghill, J.M.; Panoskaltsis-Mortari, A.; Blazar, B.R.; Serody, J.S. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood, 2009, 113(6), 1365-1374.
148. Yi, T.; Zhao, D.; Lin, C.L.; Zhang, C.; Chen, Y.; Todorov, I.; LeBon, T.; Kandeel, F.; Forman, S.; Zeng, D. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood, 2008, 112(5), 2101-2110.
149. Rochlitz, C.F. Gene therapy of cancer. Drugs Today (Barc), 2000, 36(9), 619-629.
150. Ferrantini, M.; Belardelli, F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol., 2000, 10(2), 145-157.
151. Salem, M.L.; Gillanders, W.E.; Kadima, A.N.; El-Naggar, S.; Rubinstein, M.P.; Demcheva, M.; Vournakis, J.N.; Cole, D.J. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J. Interferon Cytokine Res., 2006, 26(9), 593-608.
152. Cole, D.J.; Connolly, R.J.; Chan, M.W.; Schwaitzberg, S.D.; Byrne, T.K.; Adams, D.B.; Baron, P.L.; O'Brien, P.H.; Metcalf, J.S.; Demcheva, M.; Vournakis, J. A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamin e membrane formulation as a topical hemostatic agent. Surgery, 1999, 126(3), 510-517.
153. Salem, M.L.; Kadima, A.N.; Zhou, Y.; Nguyen, C.L.; Rubinstein, M.P.; Demcheva, M.; Vournakis, J.N.; Cole, D.J.; Gillanders, W.E. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J. Immunol., 2004, 172(9), 5159-5167.
154. Salem, M.L.; EL-Naggar, S.; Kadima, A.N.; Vournakis, J.N.; Cole, D.J.; Gillanders, W.E. Novel non-viral delivery system enhances the efficacy of DNA vaccines targeting cytotoxic T lymphocytes. 4th Annual Research Retreat, November 11th, Charleston; SC, USA, 2004.
155. Bendelac, A.; Medzhitov, R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med., 2002, 195(5), F19-F23.
156. Durand, V.; Wong, S.Y.; Tough, D.F.; Le Bon, A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol. Cell Biol., 2004, 82(6), 596-602.
157. Schnare, M.; Barton, G.M.; Holt, A.C.; Takeda, K.; Akira, S.; Medzhitov, R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol., 2001, 2(10), 947-950.
158. van Duin, D.; Medzhitov, R.; Shaw, A.C. Triggering TLR signaling in vaccination. Trends Immunol., 2006, 27(1), 49-55.
159. Takeda, K.; Akira, S. Roles of Toll-like receptors in innate immune responses. Genes Cells, 2001, 6(9), 733-742.
160. Seya, T.; Akazawa, T.; Uehori, J.; Matsumoto, M.; Azuma, I.; Toyoshima, K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res., 2003, 23(6a), 4369-4376.
161. Schwarz, K.; Storni, T.; Manolova, V.; Didierlaurent, A.; Sirard, J.C.; Rothlisberger, P.; Bachmann, M.F. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol., 2003, 33(6), 1465-1470.
162. Gearing, A.J. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell Biol., 2007, 85(6), 490-494.
163. Ishii, K.J.; Uematsu, S.; Akira, S. 'Toll' gates for future immunotherapy. Curr. Pharm. Des., 2006, 12(32), 4135-4142.
164. Salem, M.L.; Diaz-Montero, C.M.; El-Naggar, S.A.; Chen, Y.; Moussa, O.; Cole, D.J. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice. Vaccine, 2009, 27(4), 549-557.
165. Salem, M.L.; El-Naggar, S.A.; Kadima, A.; Gillanders, W.E.; Cole, D.J. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine, 2006, 24(24), 5119-5132.
166. Salem, M.L.; Kadima, A.N.; Cole, D.J.; Gillanders, W.E. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother., 2005, 28(3), 220-228.
167. Kabelitz, D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol., 2007, 19(1), 39-45.
168. Tabiasco, J.; Devevre, E.; Rufer, N.; Salaun, B.; Cerottini, J.C.; Speiser, D.; Romero, P. Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J. Immunol., 2006, 177(12), 8708-8713.
169. Gelman, A.E.; Zhang, J.; Choi, Y.; Turka, L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J. Immunol., 2004, 172(10), 6065-6073.
170. Cottalorda, A.; Verschelde, C.; Marcais, A.; Tomkowiak, M.; Musette, P.; Uematsu, S.; Akira, S.; Marvel, J.; Bonnefoy-Berard, N. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur. J. Immunol., 2006, 36(7), 1684-1693.
171. Sutmuller, R.P.; Morgan, M.E.; Netea, M.G.; Grauer, O.; Adema, G.J. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol., 2006, 27(8), 387-393.
172. Wang, R.F. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res., 2006, 66(10), 4987-4990.
173. Sutmuller, R.P.; den Brok, M.H.; Kramer, M.; Bennink, E.J.; Toonen, L.W.; Kullberg, B.J.; Joosten, L.A.; Akira, S.; Netea, M.G.; Adema, G.J. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest., 2006, 116(2), 485-494.
174. Wang, R.F.; Peng, G.; Wang, H.Y. Regulatory T cells and Toll-like receptors in tumor immunity. Semin. Immunol., 2006, 18(2), 136-142.
175. Banchereau, J.; Fay, J.; Pascual, V.; Palucka, A.K. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Novartis Found. Symp., 2003, 252, 226-235; discussion 235-228, 257-267.
176. Albert, M.L.; Jegathesan, M.; Darnell, R.B. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat. Immunol., 2001, 2(11), 1010-1017.
177. Banchereau, J.; Palucka, A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol., 2005, 5(4), 296-306.
178. Grab, D.J.; Salem, M.L.; Dumler, J.S.; Bucala, R. A role for the peripheral blood fibrocyte in leishmaniasis? Trends Parasitol., 2004, 20(1), 12.
179. Grab, D.J.; Salim, M.; Chesney, J.; Bucala, R.; Lanners, H.N. A role for peripheral blood fibrocytes in Lyme disease? Med. Hypotheses, 2002, 59(1), 1-10.
180. Takeda, K.; Akira, S. Toll-like receptors in innate immunity. Int. Immunol., 2005, 17(1), 1-14.
181. Fajardo-Moser, M.; Berzel, S.; Moll, H. Mechanisms of dendritic cell-based vaccination against infection. Int. J. Med. Microbiol., 2008, 298(1-2), 11-20.
182. Lore, K.; Betts, M.R.; Brenchley, J.M.; Kuruppu, J.; Khojasteh, S.; Perfetto, S.; Roederer, M.; Seder, R.A.; Koup, R.A. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol., 2003, 171(8), 4320-4328.
183. Edwards, A.D.; Diebold, S.S.; Slack, E.M.; Tomizawa, H.; Hemmi, H.; Kaisho, T.; Akira, S.; Reis e Sousa, C. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol., 2003, 33(4), 827-833.
184. Datta, S.K.; Redecke, V.; Prilliman, K.R.; Takabayashi, K.; Corr, M.; Tallant, T.; DiDonato, J.; Dziarski, R.; Akira, S.; Schoenberger, S.P.; Raz, E. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol., 2003, 170(8), 4102-4110.
185. Kadowaki, N.; Ho, S.; Antonenko, S.; Malefyt, R.W.; Kastelein, R.A.; Bazan, F.; Liu, Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med., 2001, 194(6), 863-869.
186. West, M.A.; Wallin, R.P.; Matthews, S.P.; Svensson, H.G.; Zaru, R.; Ljunggren, H.G.; Prescott, A.R.; Watts, C. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science, 2004, 305 (5687), 1153-1157.
187. Spaner, D.E.; Masellis, A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia, 2007, 21(1), 53-60.
188. Foldes, G.; von Haehling, S.; Anker, S.D. Toll-like receptor modulation in cardiovascular disease: a target for intervention? Expert Opin. Investig. Drugs, 2006, 15(8), 857-871.
189. Horner, A.A. Update on toll-like receptor ligands and allergy: implications for immunotherapy. Curr. Allergy Asthma Rep., 2006, 6(5), 395-401.
190. Baldridge, J.R.; McGowan, P.; Evans, J.T.; Cluff, C.; Mossman, S.; Johnson, D.; Persing, D. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther., 2004, 4(7), 1129-1138.
191. Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.; Wegner, T.; Schmook, T.; Sterry, W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br. J. Dermatol., 2003, 149(Suppl. 66), 53-56.
192. Krieg, A.M. Antiinfective applications of toll-like receptor 9 agonists. Proc. Am. Thorac. Soc., 2007, 4(3), 289-294.
193. Grohmann, U.; Bianchi, R.; Belladonna, M.L.; Silla, S.; Surace, D.; Fioretti, M.C.; Puccetti, P. Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines. Adv. Exp. Med. Biol., 1997, 417, 579-582.
194. Ahonen, C.L.; Doxsee, C.L.; McGurran, S.M.; Riter, T.R.; Wade, W.F.; Barth, R.J.; Vasilakos, J.P.; Noelle, R.J.; Kedl, R.M. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med., 2004, 199(6), 775-784.
195. Zhu, X.P.; Chen, Z.Z.; Li, C.T.; Lin, X.; Zhuang, J.L.; Hu, J.D.; Yang, T.; Xu, Z.S. In vitro inducing effect of dendritic cells cotransfected with survivin and granulocyte-macrophage colony-stimulating factor on cytotoxic T cell to kill leukemic cells. Chin. Med. J. (Engl.), 2008, 121(21), 2180-2184.
196. Tatsumi, T.; Takehara, T.; Yamaguchi, S.; Sasakawa, A.; Miyagi, T.; Jinushi, M.; Sakamori, R.; Kohga, K.; Uemura, A.; Ohkawa, K.; Storkus, W.J.; Hayashi, N. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther., 2007, 14(11), 863-871.
197. Satoh, Y.; Esche, C.; Gambotto, A.; Shurin, G.V.; Yurkovetsky, Z.R.; Robbins, P.D.; Watkins, S.C.; Todo, S.; Herberman, R.B.; Lotze, M.T.; Shurin, M.R. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J. Exp. Ther. Oncol., 2002, 2(6), 337-349.
198. Tanaka, F.; Hashimoto, W.; Robbins, P.D.; Lotze, M.T.; Tahara, H. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther., 2002, 9(21), 1480-1486.
199. Bontkes, H.J.; Kramer, D.; Ru izendaal, J.J.; Kueter, E.W.; van Tendeloo, V.F.; Meijer, C.J.; Hooijberg, E. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther., 2007, 14(4), 366-375.
200. Vujanovic, L.; Ranieri, E.; Gambotto, A.; Olson, W.C.; Kirkwood, J.M.; Storkus, W.J. IL-12p70 and IL-18 gene-Plasticity modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther., 2006, 13(8), 798-805.
201. Iinuma, H.; Okinaga, K.; Fukushima, R.; Inaba, T.; Iwasaki, K.; Okinaga, A.; Takahashi, I.; Kaneko, M. Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J. Immunol., 2006, 176(6), 3461-3469.
202. Encke, J.; Bernardin, J.; Geib, J.; Barbakadze, G.; Bujdoso, R.; Stremmel, W. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. World J. Gastroenterol., 2006, 12(44), 7118-7125.
203. Pillarisetty, V.G.; Miller, G.; Shah, A.B.; DeMatteo, R.P. GMCSF expands dendritic cells and their progenitors in mouse liver. Hepatology, 2003, 37(3), 641-652.